Combination of asundexian and rivaroxaban

The combination of asundexian and rivaroxaban addresses the limitations of monotherapies by achieving synergistic anticoagulant effects with reduced bleeding risk, enhancing thrombus reduction and patient survival in thrombotic or thromboembolic disorders.

WO2026233961A1PCT designated stage Publication Date: 2026-11-12BAYER AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062871
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-09
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current monotherapies for thrombotic or thromboembolic disorders, such as those using Vitamin K-Antagonists, heparins, factor Xa (FXa), or factor Ila (FXIa) inhibitors, face limitations including an acceptable bleeding risk, which hampers optimized antithrombotic therapy, especially with indirect inhibitors of multiple coagulation factors.

Method used

The combination of asundexian, a factor XIa inhibitor, and rivaroxaban, a factor Xa inhibitor, targets different stages of the coagulation cascade, offering synergistic anticoagulant effects without increasing bleeding risk, achieved through a fixed or non-fixed combination in various dosage forms.

Benefits of technology

The combination provides superior thrombus reduction with lower bleeding risk compared to monotherapies, allowing for potentially lower doses and longer survival times in treated patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000040_0001
    Figure IMGF000040_0001
Patent Text Reader

Abstract

The invention refers to the combination of asundexian or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and rivaroxaban or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of thrombotic or thromboembolic disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Combination of Asundexian and Rivaroxaban

[0002] The invention refers to the combination of asundexian or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and rivaroxaban or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of thrombotic or thromboembolic disorders.

[0003] Asundexian, which is (4.S')-24-chloro-4-cthyl-73-fluoro-3 -mcthoxy-32.5-dioxo-l4-(trifliioromcthyl)-32 / / -6-aza-3(4,l)-pyridina-l(l)-[l,2,3]triazola-2(l,2),7(l)-dibenzenaheptaphane-74-carboxamide, also named as 4-({(2S)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-lH-l,2,3-triazol-l-yl]phenyl}-5-methoxy-2-oxopyridin-l(2H)-yl]butanoyl}amino)-2-fluorobenz -amide, a compound of the formula (I)

[0004]

[0005] is a factor Xia inhibitor (FXIa inhibitor) and owing to this specific mechanism of action, might lead in vivo after oral administration to a safe and efficient anticoagulation. Asundexian is described in WO2017 / 005725 in example 235.

[0006] WO2022 / 189279 describes the crystalline forms of the compound of the formula (I). WO2014 / 154794 and W02017 / 005725 describe a synthesis for preparing the compound of the formula (I).

[0007] The effect of asundexian was shown in in vivo models of venous and arterial thrombosis (Heitmeier S et al., Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor Xia. JTH 2022; 20: 1400-1411). The effect of asundexian on human FXIa and the coagulation processes was evaluated in vitro in buffer and plasma (Heitmeier S et al., Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor Xia. JTH 2022; 20: 1400-1411) and ex vivo in clinical studies (Kubitza D et al., Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study. Br J Clin Pharmacol. 2022; 88: 3447-3462).

[0008] Rivaroxaban, which is 5-chloro-7V-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-l,3-oxazohdin-5-yl}methyl)-2 -thiophenecarboxamide and is depicted in formula (II) below

[0009]

[0010] is sold under the brand name Xarelto®. Rivaroxaban is described in WOOl / 47919 in example 44. Factor Xa inhibitors (FXa inhibitors) can preferably be employed in medicaments for the treatment and / or prevention of thrombotic or thromboembolic disorders. Rivaroxaban is approved as 20 mg once daily therapy for stroke prophylaxis in patients with atrial fibrillation and for treatment of existing deep vein thrombosis (DVT) or pulmonary embolisms (PE) (after the first three weeks at 15 mg twice daily), as 10 mg once daily for deep vein thrombosis prophylaxis after hip or knee replacement surgery, for venous thromboembolism prophylaxis in patients with restricted mobility, and for reduction in risk of recurrence of DVT or PE, as 2.5 mg twice daily in combination with aspirin, to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

[0011] The antithrombotic effect of rivaroxaban was shown in animal experimental investigations (Perzbom E, et al., In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939- an oral, direct Factor Xa inhibitor. JTH 2005; 3: 514-521) and in clinical studies (Kubitza D, Haas S, Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006; 15: 843-855). Combinations of Factor Xia inhibitors with Factor Xa inhibitors are mentioned in W02017 / 005725 in an extensive list of possible combination partners.

[0012] An object of the present invention is the improvement of the treatment and / or prevention of thrombotic or thromboembolic disorders in comparison to the already known monotherapies.

[0013] Another object of the present invention is the improvement of the treatment and / or prevention of thrombotic or thromboembolic disorders by administration of a combination comprising asundexian and rivaroxaban.

[0014] Asundexian may be also used as a hydrate, solvate, or a pharmaceutically acceptable salt, and rivaroxaban may be also used as a hydrate, solvate, or a pharmaceutically acceptable salt.

[0015] One compound of the combination according to the invention is asundexian or a hydrate, solvate, or a pharmaceutically acceptable salt thereof, and the other compound is rivaroxaban or a hydrate, solvate, or a pharmaceutically acceptable salt thereof.

[0016] One compound of the combination according to the invention is asundexian or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and the other compound is rivaroxaban or a pharmaceutically acceptable salt thereof.For the purpose of the present invention “pharmaceutically acceptable salts” may be salts of the compounds of the invention with inorganic or organic acids. Preferred salts are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as, for example, acetic acid, trifluoroacetic acid, propionic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.

[0017] Pharmaceutically acceptable salts which may also be mentioned are salts with conventional bases, such as, for example, alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. calcium or magnesium salts) or ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methyhnorpholine, dihydroabietylamine or methylpiperidine.

[0018] “Solvates” in the context of the invention are described as those forms of the compounds which form a complex in the solid or liquid state by coordination with solvent molecules. “Hydrates” are a specific form of the solvates in which the coordination is with water.

[0019] In the context of the present invention, the term "treatment" or "treating" includes inhibition, retardation, checking, alleviating, attenuating, restricting, reducing, suppressing, repelling or healing of a disease, a condition, a disorder, an injury or a health problem, or the development, the course or the progression of such states and / or the symptoms of such states. The term "therapy" is understood here to be synonymous with the term "treatment" .

[0020] The terms "prevention", "prophylaxis" and "preclusion" are used synonymously in the context of the present invention and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease, a condition, a disorder, an injury or a health problem, or a development or advancement of such states and / or the symptoms of such states.

[0021] The treatment or prevention of a disease, a condition, a disorder, an injury or a health problem may be partial or complete.

[0022] Surprisingly, the combination of asundexian and rivaroxaban of the present invention shows pharmacological profiles with a significantly improved efficacy versus the expected efficacy achieved by the combination of the results of the two monotherapies.

[0023] The invention therefore relates to the combination of asundexian and rivaroxaban.

[0024] The invention therefore relates to the combination of asundexian and rivaroxaban for the treatment and / or prevention of thrombotic or thromboembolic disorders.

[0025] “Combinations” mean for the purposes of the invention dosage forms which comprise the compounds in one dosage form (fixed combination), as well as in separate dosage forms (non-fixed combination (or also called kit-of-parts)) or a combination pack, which comprise the compounds separate from one another inone package. The compounds of a non-fixed combination or a combination pack can be administered simultaneously or sequentially as long as they are employed for the treatment and / or prevention of the same disease.

[0026] “Fixed combination” in the present invention is used as known to persons skilled in the art. It is defined as a combination comprising or containing asundexian and rivaroxaban, within one pharmaceutical dosage form or in one single entity.

[0027] In one embodiment according to the invention, the combination is a fixed combination comprising asundexian and rivaroxaban.

[0028] “Non-fixed combination”, also called “kit-of-parts”, in the present invention is used as known to persons skilled in the art. It is defined as a combination, wherein asundexian and rivaroxaban are present in more than one unit or dosage form. It is possible for the compounds of the non-fixed combination to be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.

[0029] The non-fixed combination is particularly advantageous if the separate compounds have to be administered in different dose intervals.

[0030] In one embodiment according to the invention, the combination is a non-fixed combination, comprising asundexian and rivaroxaban.

[0031] In a “combination pack” the compounds are included in separate dosage forms marketed in the same package. The combination may comprise a tablet as administrable dose form and an oral solution as another administrable dose form. The combination pack is used to combine two or more dose forms to describe products that are packaged together but are administered separately, sequentially, simultaneously, concurrently or chronologically staggered as independent pharmaceutical products.

[0032] The combination pack is particularly advantageous if the separate compounds have to be administered in different dose forms and / or are administered in different dose intervals.

[0033] In one embodiment according to the invention, the combination is a combination pack, comprising asundexian and rivaroxaban.

[0034] ’’Pharmaceutical dose form” and ’’dosage form” are synonyms. ’’Pharmaceutical dose form” or ’’dosage form” is the physical manifestation of a product that contains or comprises the active ingredient and / or inactive ingredients (e.g. carrier, excipients) that are intended to be delivered to the patient. ’’Dosage form” is the term used in the European Pharmacopoeia. ’’Dosage form” was previously used in Standard Terms, but the term “pharmaceutical dose form” is now used in order to harmonise with the vocabulary that is used across the Identification of Medicinal Products project.

[0035] Common dosage forms include pill, tablet, capsule, syrup, aerosol, liquid injection, granulate, powder, or solid crystal, and so on. The route of administration for drug delivery is dependent on the dosage form of the active ingredient. A granulate, a powder, or a solid crystal might be delived in a sachet.In one embodiment the fixed combination or non-fixed combination or combination pack according to the invention is a dosage form for oral administration.

[0036] In one example of the embodiment the pharmaceutical dose form according to the invention is a tablet. In another example of the embodiment the pharmaceutical dose form according to the invention is a capsule.

[0037] A fixed combination in the present invention comprises the compounds in one single pharmaceutical dose form.

[0038] A non-fixed combination in the present invention comprises the compounds in separate pharmaceutical dosage forms.

[0039] In a non-fixed combination the separate pharmaceutical dosage forms are identical.

[0040] In one example of the embodiment of a non-fixed combination, the combination comprises a first tablet comprising asundexian and a second tablet comprising rivaroxaban.

[0041] This embodiment of a non-fixed combination is not limited to the combination of two tablets. Further dosage forms, which can be used in this embodiment are mentioned above.

[0042] In a “combination pack” the separate pharmaceutical dosage forms are different.

[0043] In one example of the embodiment of a combination pack, the combination comprises a tablet comprising one compound and a capsule comprising the other compound.

[0044] This embodiment is not limited to the combination of a tablet and capsule. Further dosage forms, which can be used in this embodiment are mentioned above.

[0045] In one example of the embodiment of a combination pack, the combination comprises a tablet comprising asundexian and a capsule comprising rivaroxaban.

[0046] In another example of the embodiment of a combination pack, the combination comprises a capsule comprising asundexian and a tablet comprising rivaroxaban.

[0047] In one embodiment the combination according to the invention is administered one or more times per day. The combination according to the invention can be applied once daily (once daily administration).

[0048] A fixed combination according to the invention can be applied once daily (once daily administration; OD). In one embodiment administration is performed via the oral route once or more time per day.

[0049] In one embodiment administration of a fixed combination according to the invention is performed via the oral route once or more time per day.

[0050] In one embodiment administration is performed via the oral route two times per day (twice daily administration; BID).In one embodiment administration of a fixed combination according to the invention is performed via the oral route two times per day (twice daily administration).

[0051] The non-fixed combination or the combination pack according to the invention comprise separate dosage forms, wherein the respective dosage forms are given at the same time point.

[0052] The non-fixed combination or the combination pack according to the invention comprise separate dosage forms, wherein the respective dosage forms are given at a different time point.

[0053] The non-fixed combination or the combination pack according to the invention comprise separate dosage forms, wherein one respective dosage form is given in the morning and one respective dosage form is given in the evening.

[0054] For the purpose of the present invention, the term "thrombotic or thromboembolic disorders" include hypoxic disorders, which occur due to vessel occlusion in both, the arterial or the venous vascular system by thrombi formed mainly of fibrin and blood cells, e.g. platelets, erythrocytes and leukocytes. These events can occur at the site of thrombus formation (“thrombotic disorders”) or may happen in another area after the thrombus (or parts of it) got dislodged (“thromboembolic disorders”) or both. They can be treated and / or prevented with the combinations according to the invention.

[0055] Sometimes herein, the term “disorder” and “disease” are used as synonyms.

[0056] The combinations of the invention for the treatment and / or prevention of thrombotic or thromboembolic disorders.

[0057] The combinations of the invention are in particular suitable for the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke and ischemic strokes including

[0058] cardioembolic strokes,

[0059] such as strokes in patients with atrial fibrillation,

[0060] non-cardioembolic strokes,

[0061] such as strokes due to large or small artery diseases,

[0062] or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA. The combinations of the invention are also suitable for the treatment and / or prevention of thrombotic or thromboembolic disorders in the coronary arteries of the heart, such as acute coronary syndrome (ACS), myocardial infarction with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty, stent implantation or aortocoronary bypass.The combinations of the invention are also suitable for the treatment and / or prevention of thrombotic or thromboembolic disorders caused by occlusions of peripheral arteries, leading to peripheral artery disease, including peripheral artery occlusion, acute limb ischemia, amputation, reocclusions and restenoses after interventions such as angioplasty, stent implantation or surgery and bypass, and / or stent thrombosis.

[0063] The combinations of the invention are also suitable for the treatment and / or prevention of thrombotic or thromboembolic disorders in pulmonary, renal, retinal arteries and veins, such as pulmonary thrombosis and embolisms, venous thromboembolisms, venous thromboses, in particular in deep leg veins and kidney veins.

[0064] The combinations of the invention are also suitable for the treatment and / or prevention of venous thrombosis in medical ill patients, including patients with heart failure or with infection, and in cancer-associated thrombosis.

[0065] The combinations of the invention are therefore also suitable for the treatment and / or prevention of cardiogenic thromboembolisms,

[0066] for example brain ischemias, stroke and systemic thromboembolisms and ischemias, in patients with acute, intermittent or persistent cardiac arrhythmias,

[0067] for example atrial fibrillation,

[0068] and in patients undergoing cardioversion,

[0069] and also in patients with heart valve disorders or with artificial heart valves or with bioprosthetic valves or in patients undergoing transcatheter aortic valve replacement (TAVR),

[0070] and in patients with heart failure or ventricular thrombus formation.

[0071] The combinations of the invention are also suitable for the treatment and / or prevention of thrombi in extracorporeal systems, such as instruments for hemodialysis and extracorporeal membrane oxygenation or devices such as left ventrical assist devices.

[0072] The combinations of the invention are in particular suitable for the treatment and / or prevention of cardioembolic strokes in patients with atrial fibrillation.

[0073] The combinations of the invention are in particular suitable for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation.

[0074] The combinations of the invention are in particular suitable for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation untreated with oral anticoagulation.

[0075] The combinations of the invention are in particular suitable for the prevention of the above-mentioned disorders.

[0076] The combinations of the invention for the use in the treatment and / or prevention of thrombotic orthromboembolic disorders.

[0077] The combinations of the invention are in particular suitable for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke and ischemic strokes including

[0078] cardioembolic strokes,

[0079] such as strokes in patients with atrial fibrillation,

[0080] non-cardioembolic strokes,

[0081] such as strokes due to large or small artery diseases,

[0082] or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA. The combinations of the invention are also suitable for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders in the coronary arteries of the heart, such as acute coronary syndrome (ACS), myocardial infarction with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty, stent implantation or aortocoronary bypass.

[0083] The combinations of the invention are also suitable for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders caused by occlusions of peripheral arteries, leading to peripheral artery disease, including peripheral artery occlusion, acute limb ischemia, amputation, reocclusions and restenoses after interventions such as angioplasty, stent implantation or surgery and bypass, and / or stent thrombosis.

[0084] The combinations of the invention are also suitable for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders in pulmonary, renal, retinal arteries and veins, such as pulmonary thrombosis and embolisms, venous thromboembolisms, venous thromboses, in particular in deep leg veins and kidney veins.

[0085] The combinations of the invention are also suitable for the use in the treatment and / or prevention of venous thrombosis in medical ill patients, including patients with heart failure or with infection, and in cancer-associated thrombosis.

[0086] The combinations of the invention are therefore also suitable for the use in the treatment and / or prevention of cardiogenic thromboembolisms,

[0087] for example brain ischemias, stroke and systemic thromboembolisms and ischemias, in patients with acute, intermittent or persistent cardiac arrhythmias,

[0088] for example atrial fibrillation,and in patients undergoing cardioversion,

[0089] and also in patients with heart valve disorders or with artificial heart valves or with bioprosthetic valves or in patients undergoing transcatheter aortic valve replacement (TAVR),

[0090] and in patients with heart failure or ventricular thrombus formation.

[0091] The combinations of the invention are also suitable for the use in the treatment and / or prevention of thrombi in extracorporeal systems, such as instruments for hemodialysis and extracorporeal membrane oxygenation or devices such as left ventrical assist devices.

[0092] The combinations of the invention are therefore also suitable for the use in the treatment and / or prevention of cardioembolic strokes in patients with atrial fibrillation.

[0093] The combinations of the invention are therefore also suitable for the use in the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation.

[0094] The combinations of the invention are therefore also suitable for the use in the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation untreated with oral anticoagulation.

[0095] The combinations of the invention are therefore also suitable for the use in the prevention of the above-mentioned disorders.

[0096] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders.

[0097] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke and ischemic strokes including

[0098] cardioembolic strokes,

[0099] such as strokes in patients with atrial fibrillation,

[0100] non-cardioembolic strokes,

[0101] such as strokes due to large or small artery diseases,

[0102] or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA. The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders in the coronary arteries of the heart, such as acute coronary syndrome (ACS), myocardial infarction with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty, stent implantation or aortocoronary bypass.The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders caused by occlusions of peripheral arteries, leading to peripheral artery disease, including peripheral artery occlusion, acute limb ischemia, amputation, reocclusions and restenoses after interventions such as angioplasty, stent implantation or surgery and bypass, and / or stent thrombosis.

[0103] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders in pulmonary, renal, retinal arteries and veins, such as pulmonary thrombosis and embolisms, venous thromboembolisms, venous thromboses, in particular in deep leg veins and kidney veins.

[0104] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of venous thrombosis in medical ill patients, including patients with heart failure or with infection, and in cancer-associated thrombosis.

[0105] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of cardiogenic thromboembolisms,

[0106] for example brain ischemias, stroke and systemic thromboembolisms and ischemias, in patients with acute, intermittent or persistent cardiac arrhythmias,

[0107] for example atrial fibrillation,

[0108] and in patients undergoing cardioversion,

[0109] and also in patients with heart valve disorders or with artificial heart valves or with bioprosthetic valves or in patients undergoing transcatheter aortic valve replacement (TAVR),

[0110] and in patients with heart failure or ventricular thrombus formation.

[0111] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of thrombi in extracorporeal systems, such as instruments for hemodialysis and extracorporeal membrane oxygenation or devices such as left ventrical assist devices.

[0112] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of cardioembolic strokes in patients with atrial fibrillation.

[0113] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation.

[0114] The use of a combination of the invention for producing a medicament for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation untreated with oral anticoagulation.

[0115] The use of a combination of the invention for producing a medicament for the prevention of the above-mentioned disorders.The combinations of the invention for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders.

[0116] The combination of the invention for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke and ischemic strokes including cardioembolic strokes,

[0117] such as strokes in patients with atrial fibrillation,

[0118] non-cardioembolic strokes,

[0119] such as strokes due to large or small artery diseases,

[0120] or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA. The combination of the invention for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders in the coronary arteries of the heart, such as acute coronary syndrome (ACS), myocardial infarction with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty, stent implantation or aortocoronary bypass.

[0121] The combination of the invention for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders caused by occlusions of peripheral arteries, leading to peripheral artery disease, including peripheral artery occlusion, acute limb ischemia, amputation, reocclusions and restenoses after interventions such as angioplasty, stent implantation or surgery and bypass, and / or stent thrombosis.

[0122] The combination of the invention for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders in pulmonary, renal, retinal arteries and veins, such as pulmonary thrombosis and embolisms, venous thromboembolisms, venous thromboses, in particular in deep leg veins and kidney veins.

[0123] The combination of the invention for use in a method for the treatment and / or prevention of venous thrombosis in medical ill patients, including patients with heart failure or with infection, and in cancer-associated thrombosis.

[0124] The combination of the invention for use in a method for the treatment and / or prevention of cardiogenic thromboembolisms,

[0125] for example brain ischemias, stroke and systemic thromboembolisms and ischemias, in patients with acute, intermittent or persistent cardiac arrhythmias,

[0126] for example atrial fibrillation,and in patients undergoing cardioversion,

[0127] and also in patients with heart valve disorders or with artificial heart valves or with bioprosthetic valves or in patients undergoing transcatheter aortic valve replacement (TAVR),

[0128] and in patients with heart failure or ventricular thrombus formation.

[0129] The combination of the invention for use in a method for the treatment and / or prevention of thrombi in extracorporeal systems, such as instruments for hemodialysis and extracorporeal membrane oxygenation or devices such as left ventrical assist devices.

[0130] The combination of the invention for use in a method for the treatment and / or prevention of cardioembolic strokes in patients with atrial fibrillation.

[0131] The combination of the invention for use in a method for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation.

[0132] The combination of the invention for use in a method for the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation untreated with oral anticoagulation.

[0133] The combination of the invention for use in a method for the prevention of the above-mentioned disorders. So far, the therapeutic options are restricted to efficacious doses of Vitamin K-Antagonists, heparins, factor Xa (FXa) or factor Ila (Flla) inhibitors, which share a still acceptable bleeding risk compromise. However, the risks of bleedings are still the major hurdle for optimized antithrombotic therapy. This is even more relevant for indirect inhibitors of more than one coagulation factor, such as Vitamin K-Antagonists or heparins.

[0134] Combinations of FXa and Flla inhibition have been investigated in in vitro and in vivo settings (Gould WR et al., Inhibitors of blood coagulation factors Xa and Ila synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. JTH 2006; 4: 834-41), showing that the use of combinations of small molecule inhibitors of FXa and Flla can result in synergistic effects on the efficacy side, but might still be hampered by a risk for bleedings.

[0135] In the experiments described in the example section, combinations of asundexian and rivaroxaban demonstrated synergism in their anticoagulant effects. These over-additive effects achieved with combinations according to the invention in comparison to the respective effects with asundexian or rivaroxaban alone were not predictable as asundexian and rivaroxaban target different stages of the coagulation cascade. In particular in the case of factor Xia (FXIa) involvement the prediction was not possible, because this enzyme is involved in two processes: While it is activated by factor Xlla (FXIIa) in the intrinsic or contact pathway and leads to activation of factor Xa (FXa) two steps down in the common pathway, it is activated by thrombin in the amplification loop procedures, being in this case either two step up or down of FXa.The data in Thrombin Generation Assays with different coagulation triggers in the example section reveal that synergistic effects were present after activation via the intrinsic and extrinsic pathway. Even at higher concentrations of tissue factor, the combination of asundexian and rivaroxaban showed synergistic effects. Since it was shown before that FXIa inhibitors such as asundexian have a very low bleeding risk, the advantage of administering the combination of asundexian and rivaroxaban is that while asundexian can be administered at a high dose without increase in bleeding risk, the combination with a small dose of rivaroxaban, not enough to increase the bleeding risk either, results in superior, synergistic efficacy in thrombus reduction without an increase in bleeding risk, as was demonstrated in an in vivo model in the example section, by a combination of asundexian and rivaroxaban, which was more efficacious than both compounds alone without increasing the bleeding time. A therapeutic improvement is thus achieved by the combination according to the invention.

[0136] The combination according to the invention could provide for the administration of lesser amounts of one or both of the administered combination agents compared to monotherapy. The combination according to the invention could provide for a longer survival time with lower bleeding risk among treated patients compared to standard treatments.

[0137] The present invention includes pharmaceutical preparations which are comprised of a pharmaceutically effective amount of asundexian and rivaroxaban and pharmaceutically acceptable carrier and / or excipient. The present invention includes pharmaceutical preparations which, besides non-toxic, inert pharmaceutically suitable excipients and / or carriers, comprise one or more combinations of the invention or which consist of a combination of the invention, and processes for producing these preparations.

[0138] A “pharmaceutically effective amount” of asundexian or rivaroxaban (active ingredients) is that amount which produces a result or exerts an influence on the particular condition being treated.

[0139] A “pharmaceutically acceptable carrier” is any carrier which is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient.

[0140] An “excipient” is used as known in the art. It is a substance formulated alongside the active ingredient of a medication, included for e.g. the purpose of long-term stabilization, bulking up solid formulations that contain potent active ingredients in small amounts (thus often referred to as "bulking agents", "fillers", or "diluents"), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerns such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation or aggregation over the expected shelf life. The selection of appropriate excipients also depends upon the route of administration and the dosage form, as well as the active ingredient and other factors.The combinations of the invention are intended to be present in the above mentioned pharmaceutical preparations in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95 % by weight of the complete mixture.

[0141] The above mentioned pharmaceutical preparations may, besides the combinations of the invention, also comprise further active pharmaceutical ingredients.

[0142] The above mentioned pharmaceutical preparations can be produced in a conventional way by known methods, e.g. by mixing the active ingredient or active ingredients with the carrier(s).

[0143] Pharmaceutical compositions comprising Asundexian are described in WO2022 / 189278 and W02024 / 200335. Pharmaceutical compositions comprising Rivaroxaban are described in W02005 / 060940.

[0144] The amount of the administered active ingredient can vary widely according to such considerations as the particular compound and dosage form employed, the mode and time of administration, the period of treatment, the age, sex, and general condition of the patient treated, the nature and extent of the condition treated, the rate of drug metabolism and excretion, the potential drug combinations and drug -drug interactions, and the like.

[0145] The invention further relates to medicaments comprising at least one of the combinations defined above and, where appropriate, further active pharmaceutical ingredients.

[0146] One embodiment according to the invention refers to the combination comprising asundexian in an amount of 25 mg to 100 mg. One embodiment according to the invention refers to the combination comprising asundexian in an amount of 50 mg to 100 mg.

[0147] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 to 100 mg, 50 to 90 mg, 50 to 80 mg or 50 to 60 mg.

[0148] In one embodiment the combination according to the invention comprises asundexian in an amount of 50, 60, 70, 80, 90 or 100 mg.

[0149] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg.

[0150] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg.

[0151] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each.

[0152] In one embodiment the combination according to the invention comprises asundexian in an amount of 60 mg, where the 60 mg are given two times a day at 30 mg each.

[0153] In one embodiment the combination according to the invention comprises asundexian in an amount of 70mg, where the 70 mg are given two times a day at 35 mg each.

[0154] In one embodiment the combination according to the invention comprises asundexian in an amount of 80 mg, where the 80 mg are given two times a day at 40 mg each.

[0155] In one embodiment the combination according to the invention comprises asundexian in an amount of 90 mg, where the 90 mg are given two times a day at 45 mg each.

[0156] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each.

[0157] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 1.0 to 10.0 mg. In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.0 to 6.0 mg. In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.0 to 5.0 mg. In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.0 to 4.0 mg.

[0158] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 1.0 mg.

[0159] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.0, 3.0, 4.0 or 5.0 mg.

[0160] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.5 mg.

[0161] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 1.0 mg, where the 1.0 mg are given two times a day at 0.5 mg each.

[0162] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.0 mg, where the 2.0 mg are given two times a day at 1.0 mg each.

[0163] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.5 mg, where the 2.5 mg are given two times a day at 1.25 mg each.

[0164] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 2.6 mg, where the 2.6 mg are given two times a day at 1.3 mg each.

[0165] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 3.0 mg, where the 3.0 mg are given two times a day at 1.5 mg each.

[0166] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 4.0 mg, where the 4.0 mg are given two times a day at 2.0 mg each.

[0167] In one embodiment the combination according to the invention comprises rivaroxaban in an amount of 5.0 mg, where the 5.0 mg are given two times a day at 2.5 mg each.In one embodiment the combination according to the invention comprises asundexian in an amount mentioned above and rivaroxaban in an amount mentioned above.

[0168] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 to 100 mg and rivaroxaban in an amount of 2.0 to 5.0 mg.

[0169] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 2.0 mg.

[0170] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 2.0 mg.

[0171] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 2.5 mg.

[0172] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 2.5 mg.

[0173] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 2.6 mg.

[0174] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 2.6 mg.

[0175] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 3.0 mg.

[0176] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 3.0 mg.

[0177] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 4.0 mg.

[0178] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 4.0 mg.

[0179] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg and rivaroxaban in an amount of 5.0 mg.

[0180] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg and rivaroxaban in an amount of 5.0 mg.

[0181] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 2.0 mg, where the 2.0 mg are given two times a day at 1.0 mg each.

[0182] In one embodiment the combination according to the invention comprises asundexian in an amount of 100mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 2.0 mg, where the 2.0 mg are given two times a day at 1.0 mg each.

[0183] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 2.5 mg, where the 2.5 mg are given two times a day at 1.25 mg each.

[0184] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 2.5 mg, where the 2.5 mg are given two times a day at 1.25 mg each.

[0185] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 2.6 mg, where the 2.6 mg are given two times a day at 1.3 mg each.

[0186] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 2.6 mg, where the 2.6 mg are given two times a day at 1.3 mg each.

[0187] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 3.0 mg, where the 3.0 mg are given two times a day at 1.5 mg each.

[0188] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 3.0 mg, where the 3.0 mg are given two times a day at 1.5 mg each.

[0189] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 4.0 mg, where the 4.0 mg are given two times a day at 2.0 mg each.

[0190] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 4.0 mg, where the 4.0 mg are given two times a day at 2.0 mg each.

[0191] In one embodiment the combination according to the invention comprises asundexian in an amount of 50 mg, where the 50 mg are given two times a day at 25 mg each, and rivaroxaban in an amount of 5.0 mg, where the 5.0 mg are given two times a day at 2.5 mg each.

[0192] In one embodiment the combination according to the invention comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 5.0 mg, where the 5.0 mg are given two times a day at 2.5 mg each.

[0193] Nevertheless, it may in some cases be advantageous to deviate from the amounts specified, depending onbody weight, individual behaviour towards the active ingredient, type of preparation and time or interval over which the administration is affected. For instance, less than the aforementioned minimum amounts can be sufficient in some cases, while the upper limit specified has to be exceeded in other cases.

[0194] In the case of administration of relatively large amounts, it can be advisable to divide these into several individual doses over the day.

[0195] The present invention also relates to a method for using the combination, to treatment and / or prevention of thrombotic or thromboembolic disorders. This method comprises administering to a mammal in need thereof, including a human, an amount of the combination, which is effective to treat the disorder.

[0196] The combination of the invention is administed to a human in need thereof to treat the disorders mentioned above.

[0197] In one embodiment, the combination comprises asundexian and rivaroxaban, wherein the combination is used in the treatment and / or prevention of thrombotic or thromboembolic disorders selected from the disorders mentioned above.

[0198] The present invention further provides the use of the combination of the invention for the preparation of a pharmaceutical composition for the treatment and / or prevention of thrombotic or thromboembolic disorders selected from the disorders mentioned above.

[0199] The present invention further provides the use of the combination of the invention for production of a medicament for the treatment and / or prevention of thrombotic or thromboembolic disorders selected from the disorders mentioned above.

[0200] A low-dose rivaroxaban combined with asundexian leads to a potent synergistic antithrombotic effect and is superior to the effect of the respective monotherapy with asundexian or rivaroxaban alone.

[0201] Rivaroxaban, given in dosages which show no antithrombotic effect when used alone, leads in combination with asundexian, to a considerable increase in the potency of the antithrombotic effect of asundexian in a thrombosis model.

[0202] Examples

[0203] A _ Assessment of the pharmacological activities of asundexian and rivaroxaban

[0204] Asundexian and rivaroxaban act in particular as selective inhibitors of coagulation factor Xia and coagulation factor Xa, respectively.

[0205] Inhibitors of the coagulation factors are referred to as "selective" when the IC50 values for the inhibition of their main target are 100-fold, preferably 500-fold, in particular 1000-fold, smaller than the IC50 values for the inhibition of other serine proteases, in particular thrombin, plasmin and trypsin, reference being made concerning the test methods for the selectivity to the test methods of Examples A-l) a.1) and a.2) described below.Asundexian and rivaroxaban human doses and the corresponding trough (Ctrough) and peak (Cmax) values are published in:

[0206] A: W. Mueck, et al., Clin. Pharmacokinet., 2014, 53(1), 1-16.

[0207] B: W. Mueck, et al., Thromb. Haemost., 2008, 100, 453-461.

[0208] C: L. Zhang, et al, Ther. Adv. Cardiovasc. Dis., 2019, Vol. 13, 1-15.

[0209] D: D. Kubitza, et al., Eur. J. Clin. Pharmacol., 2005, 61, 873-880.

[0210] E: A. Yassen, et al., CPT: Pharmacometrics & Systems Pharmacology, 2026, 15:e70142.

[0211] Cmax: maximum concentration; Ctrough: concentration at trough, prior to the next dose; Cav: average concentration during dosing interval; OD: once daily; BID: twice daily

[0212] Dose Cmax Cmax Ctrough Ctrough

[0213] Regimen Literature Rivaroxaban (pg / L) (pM) (Pg / L) (pM)

[0214] 20 mg OD 249 0.6 44 0.1 A

[0215] 222.6 0.5 22.3 0.05 B

[0216] 270 0.6 26 0.06 A

[0217] 10 mg OD 124.6 0.3 9.1 0.02 B

[0218] 5 mg BID 86.3 0.2 33.4 0.08 C

[0219] 39.8 0.1 8.4 0.02 B

[0220] 85.3 0.02 D

[0221] 2.5 mg BID 45.8 0.1 17.9 0.04 C

[0222] Based on ACS data 1.25 mg BID 0.05 0.02

[0223]

[0224] mentioned in C

[0225] Dose Cmax (pg / Cmax Ctrough Ctrough

[0226] Regimen Literature Asundexian L) (pM) (Pg / L) (pM)

[0227] 50 mg OD 1502 2.53 789 1.33 E

[0228] Cav (pg / L) Cav (pM)

[0229] based on PACIFIC- 50 mg BID 2261 3.81 AF 50 mg OD data

[0230]

[0231] mentioned in E

[0232] Human @50 mg OD in AF Patients

[0233] Rabbit (see Literature E)

[0234] Dose 6 mg / kg Ctrough Cmax

[0235] Exposure (ug / L) 1315 789 1502

[0236] Exposure (pM) 2.22 1.33 2.53

[0237] fu (%) 13.8 6.4

[0238] affinity ratio 3

[0239] (human / rabbit)

[0240] estimated human Eq. 1.59

[0241] (pM)

[0242] rel. to observed 63%

[0243] exposure at Cmax (%)

[0244] rel. to observed 110%

[0245]

[0246] exposure at Ctrough (%)The biological properties of asundexian and rivaroxaban can be ascertained by the following methods.

[0247] A-l) In vitro characterization of combinations of asundexian and rivaroxaban

[0248] a.l) Determination of factor Xa (FXa) or factor Xia (FXIa) inhibition in buffer

[0249] The inhibitory potencies of rivaroxaban and asundexian on FXa or FXIa were determined by conducting microtitre plate-based biochemical assays, which utilize the turnover of peptidic substrates of FXa or FXIa by the respective enzymes. The cleavage of the C-terminal chromogenic or Anorogenic moieties from the rest of the peptide resulted in an increase in light absorption or Huorescence over time. Depending on their concentrations, the inhibitors led to a reduction in absorption or Huorescence substance concentrations resulting in 50% enzyme inhibition were calculated and reported as IC50. The inhibitory constant (Ki) was calculated according to the Cheng-Prusoff equation (Ki = IC50 / I + [S] / Km), where [S] is the substrate concentration, and Km is the Michaelis-Menten constant. Km was determined from a Lineweaver-Burk plot.

[0250] FXIa inhibition

[0251] The test substances were dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 pM to 0.0078 pM; resulting Anal concentrations in the test: 50 pM to 0.00013 pM). In each case 1 pL of the diluted substance solutions was placed into the wells of white microtitre plates from Greiner (384 wells). 20 pL of assay buffer (50 mM of Tris / HCl pH 7.4; 100 mM of sodium chloride; 5 mM of calcium chloride; 0.1% of bovine serum albumin) and 20 pL of factor Xia from Kordia (0.45 nM in assay buffer) were then added successively. After 15 min of incubation, the enzyme reaction was started by addition of 20 pL of the factor Xia substrate Boc-Glu(OBzl)-Ala-Arg-AMC dissolved in assay buffer (10 pM in assay buffer) from Bachem, the mixture was incubated at room temperature (22°C) for 30 min and fluorescence was then measured (excitation: 360 nm, emission: 460 nm). The measured emissions of the solutions with test substance were compared to those of control samples and IC50 values were calculated from the concentration / activity relationships.

[0252] For asundexian, in the screening modus during compound optimization an IC50 of 0.92 nM was determined, in-depth characterization resulted in a Ki of 1.0 nM, while the value for rivaroxaban is > lOpM.

[0253] FXa inhibition

[0254] The test substances were dissolved in various concentrations in DMSO as described above and incubated with human FXa (0.5 nM dissolved in 50 mM tris buffer [C,C,C-tris(hydroxymethyl)aminomethane], 150 mM NaCl, 0.1% BSA (bovine serum albumine), pH = 8.3) at 25°C for 10 minutes. Pure DMSO served as control for 100% enzyme activity. The chromogenic substrate (150 pM Pefachrome® FXa from Pentapharm) was then added. After incubation at 25°C for 20 minutes, the extinction at 405 nm was determined. The extinctions of the test mixtures with test substance were compared with the control mixtures without test substance, and the IC50 values were calculated therefrom.The Ki of rivaroxaban is 0.7 nM, while the value for asundexian is > 1 pM.

[0255] a.2) Selectivity determination

[0256] To demonstrate the selectivity of the substances with respect to factor Xia and factor Xa inhibition, the test substances were examined for their inhibition of a panel of other human serine proteases, such as thrombin, trypsin, plasmin, and tissue plasminogen activator (tPA). The determinations were carried out in microtitre plates. To determine the enzymatic activity of thrombin (0.02 nM from Kordia), trypsin (42 mU / ml from Sigma), plasmin (0.1 pg / ml from Kordia) and tPA (1 nM from Kordia) in the presence of the test compounds, these enzymes were dissolved (50 mM of Tris buffer [C,C,C-tris(hydroxymethyl)aminomethane], 100 mM of sodium chloride, 0.1% BSA [bovine serum albumin], 5 mmol / 1 of calcium chloride, pH 7.4) and incubated for 15 min with DMSO with or without the test substances in various concentrations. The enzymatic reaction was then started by addition of the appropriate substrates (5 pM of Boc-Asp(OBzl)-Pro-Arg-AMC from Bachem for thrombin, 5 pM of Boc-Ile-Glu-Gly-Arg-AMC from Bachem for Trypsin, 50 pM of MeOSuc-Ala-Phe-Lys-AMC from Bachem for plasmin and 5 pM of CH3SO2-D-Phe-Gly-Arg-AMC from Pentapharm for tPA). After an incubation time of 30 min at 22°C, fluorescence was measured (excitation: 360 nm, emission: 460 nm). The measured emissions of the test batches with test substance were compared to the control samples with DMSO alone, and the IC50 values were calculated from the concentration / activity relationships.

[0257] a.3) Combinations of asundexian and rivaroxaban in the Thrombin Generation Assay according to Hemker

[0258] The effects of the test substances and their combinations in the Thrombin Generation Assay according to Hemker were determined in vitro in human plasma. Human whole blood was cautiously drawn from healthy volunteers and collected in lOmL-S-Monovettes (Sarstedt) containing a sodium citrate solution to yield a mixing ratio of sodium citrate / blood of 1 / 9 with a 0.11 mol / L sodium citrate. Immediately after the blood drawing, the mixture was centrifuged twice at about 2500 g for 15 minutes (20-25°C, low break). The supernatant, platelet-poor plasma (PPP), was collected and stored at -20°C. The platelet-poor plasma samples of 10 healthy donors were pooled and stored at -20°C.

[0259] In this assay, the activity of thrombin in plasma was determined over time by measuring the fluorescent cleavage products of the substrate 1-1140 (Z-Gly-Gly-Arg-AMC, Bachem) after start of the coagulation system with reagents of either the extrinsic or the intrinsic coagulation pathway. PPP Reagent (Diagnostica Stago) or Dade Actin FS (Siemens) were used as such triggers: Final concentrations in the assay of 5, 0.3 pM of tissue factor were prepared from the PPP Reagent Kit (Diagnostica Stago) by dilution and phospholipids (TGT, Rossix) were added to always achieve a final concentration of 4 pM. Final concentration of 0.42% Actin FS in the assay were prepared by adding 96 pL of an aqueous solution of 0.5 mM phospholipids and 1854 pL water to 50 pL Actin FS.

[0260] Varying concentrations of the combination of both test substances were prepared: Rivaroxaban wasdissolved in DMSO to achieve a 10 mM stock solution, which was then further diluted in DMSO in order to result in plasma concentrations of 0, 0.025, 0.05, 0.1, 0.2 and 0.4 pM in the test. Asundexian was dissolved in DMSO to achieve a 10 mM stock solution, which was then further diluted in DMSO in order to result in plasma concentrations of 0, 0.25, 0.75, 1.5, 2.5, 5 and 10 pM in the test.

[0261] The amidolytic activity of a thrombin calibrator from Thrombinoscope was used for calculating the thrombin activity in a plasma sample.

[0262] The test was carried out according to the specifications of the provider (Diagnostica Stago) with specific modifications: In a 96-well plate, 1 pL of each test substance in DMSO or of the solvent and 80 pL of plasma were mixed and 20 pL of one of the coagulation triggers or the thrombin calibrator were added. Subsequently, the mix was incubated at 37°C for 10 min. After addition of 20 pL of 2.5 mM thrombin substrate in 20 mM Hepes, 60 mg / ml of BSA, 102 mM calcium chloride, the fluorescence was measured every 20 s over a period of 90 min using a fluorometer (Fluoroskan, Thermo Electron) at 390 / 460 nm (extinction / emission). Using the Thrombinoscope software, the thrombin concentration was calculated overtime and displayed in the thrombogram. The following parameters were determined: the Lag Time as the time, when significant thrombin generation is initiated, the Peak Height as the maximum thrombin concentration, the ETP (endogenous thrombin potential) as the area under the thrombin concentration -time curve and the Velocity Index calculated from the slope of the curve between the start of thrombin generation and the peak concentration. The experiments were conducted 6 times on different days.

[0263] For each of the coagulation triggers (5, 0.3 pM tissue factor and 0.42% Actin FS) the impact of the combinations on the anticoagulation result parameters Peak Height, ETP and Velocity Index is displayed as “Obs. inh. (%)” (observed mean inhibition), as arithmetic means of signal reduction versus DMSO without test substance as control (in percent), whereas the impact of the combinations on the anticoagulation result parameter Lag Time is displayed as “Obs. prolong, (xfold)” (observed prolongation), as geometric means of the Lag Time prolongation (ratio to control).

[0264] Synergy in the sense of this invention is defined as the excess of the observed effect generated by the combination of the two compounds versus the expected additive effect of the individual compounds.

[0265] Synergy can be investigated by comparing the observed effect with the expected effect resulting from mathematical models. In this invention the Bliss Independence Model was used to estimate the expected effect. It was introduced for the first time in 1939 (Bliss CI, The toxicity of poisons applied jointly. Ann Appl Biol 1939; 2&. 585-615) and is one of the most used models to investigate synergy.

[0266] According to the Bliss Independence Model the expected effect of two drugs A and B can be determined as follows:

[0267] lABexp = IA+(1—IA) IB = IA+IB—(IA’IB) (1) where ExBexp is the expected effect for the combination, and IA and IB are the estimated effects of the drugsA and B administered alone, respectively. This model is applicable if both compounds are active simultaneously via independent interaction sites on the target pathway and is often used when pathways are inhibited, which applies to the inhibition of proteases in the coagulation system and is therefore named lx. Synergy can be concluded if the observed effect lABobs resulting from the combination of drug A and drug B is stronger than the expected effect ExBexp estimated by the Bliss Independence Model:

[0268] Synergy: Observed effect lABobs - expected effect LxBexp > 0%. (2) The effect values for IA and IB in the Bliss Independence Model approach are applied as fractional effect between 0 and 1, where 0 is the lack of effect (reported in Tables 1A to 1H as 0%) and 1 is the maximum possible effect (e.g. full inhibition) in the investigated system (reported in Tables 1A to 1H as 100%). A requirement to apply the Bliss Independence Model is the quantification of the maximum possible effect (e.g. full inhibition) to assign the effect probabilities to each single drug.

[0269] Assessment of synergy in case of the result parameters Peak Height, ETP and Velocity Index The result parameters Peak Height, ETP and Velocity Index decrease, when coagulation factors are inhibited. The maximum possible effect is to reduce the parameter value to zero (i.e. full inhibition).

[0270] The performed calculations including the derivation of IA (for asundexian) and IB (for rivaroxaban) as required to calculate the expected effect lABexp for the drug combination according to the Bliss Independence Model, are described in the following steps: A 3 -parameter Emax model - with the maximum possible effect (Emax), the control effect (Eo), and the asundexian concentration ([ASN]) producing the half maximal effect (EC50) as parameters - was fitted to the single drug concentration response data from all experiments according to the following equation:

[0271] Efitted = Eo - (Emax• [ASN]) / (EC50 + [ASN]) (3) Subsequently, the inhibition for asundexian alone was calculated based on the fitted data as

[0272] IA = 1 - (Efitted / Eo), (4)

[0273] where Efitted indicates the fitted effect value from the 3 -parameter Emax model obtained by applying equation (3) for each asundexian concentration used in the experiment. The inhibition ranges from 0 (Efitted = Eo, no inhibition [0%] at all) to 1 (Efitted = 0, full inhibition [100%]) which corresponds to the maximum achievable effect. The inhibition IB for rivaroxaban alone was calculated accordingly. Usexp was calculated according to the Bliss Independence Model (see equation (1)) (displayed as “Exp. inh. (%)” in Tables IA to 1H). The observed inhibition lABobs® for the combination of asundexian and rivaroxaban per experiment i was calculated using the observed value EABobs® for the combination divided by the observed control value Eoobs(i)

[0274] lABobs(i) 1—(EABobs(i) / Eoobs(i)). (5)

[0275] The difference between the observed effect and the expected effect (lABobs® - ExBexp) was calculated perexperiment and the arithmetic mean (displayed as “Synergy (%)” in Tables 1A to 1H) and 95% confidence interval (lower limit displayed as “11 95%Q” in Tables 1A to 1H) over all experiments was calculated. A value of the lower limit of the 95% confidence interval greater than 0 is considered indicative for synergism according to equation (2).

[0276] Assessment of synergy in case of the result parameter Lag Time

[0277] The Lag Time increases when coagulation factors are inhibited. There is no physiological maximum effect of this result parameter which would correspond to a full inhibition of the respective coagulation factors. Therefore, the end of the observation period in the experiment (90 min) is a reasonable choice with physiological and clinical relevance.

[0278] While the calculations were in general similar to the synergy calculations described before, the following differences resulted from the special situation described for Lag Time:

[0279] The 3 -parameter Emaxmodel was fitted to the single drug concentration response data from all experiments according to the following equation instead of equation (3):

[0280] Efitted = Eo + (Emax• [ASN]) / (EC50 + [ASN]) (6) Furthermore, instead of equation (4) percent inhibition for asundexian alone (or rivaroxaban) was calculated based on the fitted data as

[0281] IA = (Efitted - Eo) / (Max - Eo), (7)

[0282] where Efitted indicates the fitted effect from the 3 -parameter Emaxmodel, and Max is the maximum possible effect which was selected as a Lag Time of 90 minutes as explained above. The inhibition ranges from 0 (Efitted = Eo, no inhibition [0%] at all equivalent to no prolongation) to 1 (Efitted = Max, full inhibitory effect of 100% equivalent to maximum possible prolongation according to assumptions).

[0283] Likewise, instead of equation (5) the observed inhibition lABobs® for the combination of asundexian and rivaroxaban per experiment i was calculated using the observed value EABobs® for the combination and the observed control value Eo0bs®as follows:

[0284] lABobs® (EABobs® " Eciobs®) / (Max — Eoobs®). (9)

[0285] The results for the different coagulation triggers and parameters are displayed in Tables 1A to 1H. Combinations of the two compounds, for which the lower confidence interval for the difference of observed and expected inhibition is above 0%, are regarded synergistic under the conditions of the experiments for a certain parameter.

[0286] With a focus on the concentrations linked to human doses, in Tables 1A to 1H the results for 1.5 pM, 2.5 pM and 5 pM asundexian were summarized, reflecting the 50 mg once daily dose in trough and peak and the potentially highest values achieved with a 50 mg twice daily, while in the rivaroxaban case the 0.05 and 0.1 pM concentrations are related to the trough and peak of the 2.5 mg twice daily dosing. Furthermore, 0.4pM rivaroxaban corresponds to the peak concentration close to the highest administered dose of 20 mg once daily which is in current clinical use.

[0287] As shown in Tables 1A to 1H, after stimulation with an intrinsic trigger (Actin FS), concentrationdependent increases in Peak Height-, ETP-, and Velocity Index inhibition and in the lag time ratio were observed, accompanied by synergistic effects, which were only missing in the lowest rivaroxaban dose. After stimulation with 5 pM tissue factor, the Peak Height-, ETP-, and Velocity Index inhibition showed consistent synergism, whereas the effects on the Lag Time ratio were smaller.

[0288] After stimulation with 0.3 pM tissue factor, the effects on the Lag Time ratio were greater than with 5 pM tissue factor and synergistic effects were observed.

[0289] In addition to the displayed results with calculation of IA and IB using an Emax model, the observed values for asundexian and rivaroxaban alone were also used for calculation of IA and IB as sensitivity analysis. The respective synergy calculations led to very similar results.

[0290] An area of combinations of concentrations of asundexian and rivaroxaban was identified, in which synergistic effects were observed under various conditions and with different parameters of the Thrombin Generation Assay.

[0291] The synergistic improvement versus the current monotherapy with rivaroxaban can for example be illustrated for Peak Height inhibition after activation of the intrinsic pathway by 0.42% Actin FS: 0.4 pM rivaroxaban alone (peak of 20 mg once daily tablet) results in mean Peak Height inhibition of 58%. Similar inhibition can also be achieved with only 0.05 pM rivaroxaban when adding 1.5 pM asundexian exhibiting a synergistic effect of 15.5%. Increasing the asundexian concentration further to e.g. 2.5 pM results in even higher mean inhibition of 65.8% with a synergistic effect of 17.3%.

[0292] Likewise, multiple synergistic effects for other activation triggers and endpoints lead to achievement of a similar or higher effect than 20 mg once daily rivaroxaban alone, but with a smaller rivaroxaban concentration in combination with asundexian.

[0293] Table IA: Thrombin Generation Assay with intrinsic pathway activation with 0.42% Actin FS (ASN = asundexian; Riva = rivaroxaban; Obs. inh. (%) = observed mean inhibition; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (lABexp); Synergy(%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 11 95%CI = lower limit of the 95% confidence interval for synergy)Peak Height Velocity Index ETP

[0294] Obs. Exp. Syn- 11 Obs. Exp. Syn- 11 Obs. Exp. Syn- 11 [ASN] [Riva] inh. inh. ergy 95% inh. inh. ergy 95% inh. inh. ergy 95% (pM) (pM) (%) (%) (%) CI (%) (%) (%) CI (%) (%) (%) CI 1.5 0.025 39.0 35.0 4.0 -5.3 46.1 52.9 -6.7 -20.4 24.5 24.6 -0.1 -6.0 1.5 0.05 57.9 42.4 15.5 11.4 66.9 59.1 7.8 0.3 30.3 28.7 1.6 -4.5 1.5 0.1 70.3 51.4 18.9 15.1 76.9 66.6 10.3 3.3 38.3 32.0 6.3 2.1 1.5 0.2 79.7 60.1 19.5 16.1 84.1 73.7 10.4 6.3 46.2 34.1 12.1 6.3 2.5 0.025 57.6 41.9 15.7 7.9 68.8 60.3 8.5 -2.6 33.1 28.5 4.6 1.2 2.5 0.05 65.8 48.5 17.3 12.2 75.1 65.6 9.5 2.5 34.9 32.4 2.5 -3.6 2.5 0.1 72.8 56.5 16.3 11.8 79.3 71.9 7.4 0.4 40.4 35.5 4.9 -1.0 2.5 0.2 84.4 64.4 20.0 16.6 88.6 77.9 10.7 7.7 54.5 37.5 17.0 10.6 5.0 0.025 61.4 51.2 10.2 4.6 73.0 68.4 4.6 -4.7 35.4 34.0 1.4 -4.4 5.0 0.05 72.5 56.7 15.8 11.5 81.2 72.6 8.7 5.0 40.9 37.5 3.3 -5.5 5.0 0.1 81.4 63.5 17.9 14.5 87.0 77.6 9.5 6.5 51.7 40.4 11.3 5.9 5.0 0.2 88.7 70.1 18.6 15.5 91.7 82.4 9.4 5.8 61.8 42.3 19.5 11.6

[0295]

[0296] 0.0 0.4 58.0 64.3 27.8

[0297] Table IB: Thrombin Generation Assay with intrinsic pathway activation with 0.42% Actin FS (ASN = asundexian; Riva = rivaroxaban; Obs. inh. (%) = observed mean inhibition; calc. inh. by ASN (IA) (%) = calculated inhi rition by asundexian alone in ? 4>; calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alo ne in %)

[0298] Peak Height Velocity Index ETP

[0299] Obs. Calc. inh. Calc. inh. Obs. Calc. inh. Calc. inh. Obs. Calc. inh. Calc. inh.

[0300] [ASN] [Riva] inh. by ASN by Riva inh. by ASN by Riva inh. by ASN by Riva (pM) (pM) (%) (IA) (%) (IB) (%) (%) (IA) (%) (IB) (%) (%) (IA) (%) (IB) (%) 1.5 0.0 24.8 23.7 39.8 43.0 13.1 12.3

[0301] 2.5 0.0 32.9 31.7 53.6 52.0 17.5 16.9

[0302] 5.0 0.0 39.0 42.7 56.4 61.7 21.3 23.2

[0303] 0.0 0.025 20.5 - 14.9 22.2 - 17.4 18.3 - 14.0 0.0 0.05 21.5 - 24.5 23.8 - 28.3 14.5 - 18.7 0.0 0.1 38.0 - 36.3 44.4 - 41.4 22.0 - 22.4 0.0 0.2 47.4 - 47.8 52.9 - 53.9 25.2 - 24.9

[0304]

[0305] 0.0 0.4 58.0 - 56.8 64.3 - 63.4 27.8 - 26.3

[0306] Table 1C: Lag Time from Thrombin Generation Assay with intrinsic pathway activation with 0.42 % Actin FS (ASN = asundexian; Riva = rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of Lag Time (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (lABexp); Synergy (%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 11 95%CI = lower limit of the 95% confidence interval for synergy)0.42 % Actin FS; Lag Time

[0307] Calc. inh.

[0308] [ASN] [Riva] Obs. prolong. from obs. Exp. inh. Synergy 11 95%

[0309] (pM) (pM) (xfold) (%) (%) (%) CI

[0310] 1.5 0.025 2.43 9.7 9.0 0.7 -2.2 1.5 0.05 2.92 12.8 9.5 3.3 1.9 1.5 0.1 3.43 16.4 10.3 6.1 2.5 1.5 0.2 3.81 18.8 11.4 7.5 5.2 2.5 0.025 3.34 15.6 12.6 3.1 0.9 2.5 0.05 3.56 17.0 13.1 3.9 2.3 2.5 0.1 3.72 18.1 13.8 4.2 3.1 2.5 0.2 4.85 25.9 14.9 11.0 6.8 5.0 0.025 3.83 18.9 18.3 0.6 -2.1 5.0 0.05 4.32 22.2 18.8 3.4 0.1 5.0 0.1 5.08 27.6 19.5 8.0 1.1 5.0 0.2 6.31 35.7 20.5 15.2 9.6

[0311]

[0312] 0.0 0.4 1.71

[0313] Table ID: Lag Time from Thrombin Generation Assay with intrinsic pathway activation with 0.42 % Actin FS (ASN = asundexian; Riva rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of Lag Time (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Calc. inh. by ASN (IA) (%) = calculated inhibition by asundexian alone in %; Calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alone in %)

[0314] 0.42 % Actin FS, Lag Time

[0315] Calc. inh. Calc. inh.

[0316] [ASN] [Riva] Obs. prolong. from obs. by ASN Calc. inh. by (pM) (pM) (xfold) (%) (IA) (%) Riva (IB) (%) 1.5 0.0 2.46 9.8 8.3

[0317] 2.5 0.0 2.97 13.2 12.0

[0318] 5.0 0.0 3-48 16.6 17.8

[0319] 0.0 0.025 1.18 1.2 - 0.7

[0320] 0.0 0.05 1 19 1.3 - 1.3

[0321] 0.0 0.1 1-39 2.6 - 2.1

[0322] 0.0 0.2 1-44 3 0 - 3.3

[0323]

[0324] 0.0 0.4 1.71 4.9 - 4.5

[0325] Table IE: Thrombin Generation Assay with extrinsic pathway activation with 5 pM tissue factor (ASN = asundexian; Riva = rivaroxaban; Obs. inh. (%) = observed mean inhibition; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (lABexp); Synergy (%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 11 95%CI = lower limit of the 95% confidence interval for synergy)Peak Height Velocity Index ETP Obs. Exp. Syn- 11 Obs. Exp. Syn- 11 Obs. Exp. Syn- 11 [ASN] [Riva] inh. inh ergy 95% inh. inh. ergy 95% inh. inh. ergy 95% (pM) (pM) (%) (%) (%) CI (%) (%) (%) CI (%) (%) (%) CI 1.5 0.025 65.4 58.1 7.3 5.2 80 73.3 6.7 3.6 32.8 22 10.7 6 1.5 0.05 73.5 67.8 5.7 4.4 88.1 82.2 6 4.7 37.9 26.7 11.2 8.7 1.5 0.1 80.7 76.7 4 3.5 93 89.4 3.6 3.1 46.6 34.1 12.4 10.2 1.5 0.2 87.6 83.3 4.3 4 96.3 94.4 2 1.8 59.5 44.1 15.4 13.4 2.5 0.025 67.3 60.5 6.8 4.8 82.6 75.5 7 5.2 33.3 23.5 9.9 5.6 2.5 0.05 75.6 69.6 6 3.9 89.8 83.6 6.2 4.8 40.7 28.1 12.6 8.7 2.5 0.1 82.4 78 4.4 3.9 93.9 90.3 3.6 3.3 49.7 35.3 14.4 12.6 2.5 0.2 88.9 84.2 4.6 4 96.9 94.8 2.1 1.9 62.2 45.2 17 15 5.0 0.025 69.4 62.5 6.9 5.7 84 77.5 6.6 4.6 35.8 24.8 11.1 8.2 5.0 0.05 76.6 71.2 5.4 3.5 90.4 84.9 5.4 4.2 41.2 29.3 11.9 8.3 5.0 0.1 83.2 79.1 4.1 3.4 94.4 91.1 3.4 3 51.1 36.4 14.7 12.1 5.0 0.2 89.3 85.1 4.3 3.8 97.1 95.2 1.8 1.7 62.3 46.1 16.2 13.7

[0326]

[0327] 0.0 0.4 82.6 94.2 48.2

[0328] Table IF: Thrombin Generation Assay with extrinsic pathway activation with 5 pM tissue factor (ASN = asundexian; Riva = rivaroxaban; Obs. inh. (%) = observed mean inhibition; calc. inh. by ASN (IA) (%) = calculated inhibition by asundexian alone in %; calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alone in %)

[0329] Peak Height Velocity Index ETP

[0330] Calc. Calc. Calc. Calc. Calc. Calc. Obs. inh. by inh. by Obs. inh. by inh. Obs. inh. by inh. by [ASN] [Riva] inh. ASN Riva inh. ASN by Riva inh. ASN Riva (IB) (pM) (pM) (%) (IA) (%) (IB) (%) (%) (IA) (%) (IB) (%) (%) (IA) (%) (%) 1.5 0.0 35.6 36 48.2 48.3 15.7 16.5

[0331] 2.5 0.0 38.8 39.6 50.2 52.6 17.7 18

[0332] 5.0 0.0 41.7 42.8 55.1 56.4 19.1 19.4

[0333] 0.0 0.025 36 . 34.5 47.2 . 48.4 10.8 . 6.6 0.0 0.05 49.6 . 49.6 65.9 . 65.5 14 . 12.2 0.0 0.1 63.1 . 63.5 81.3 . 79.5 23 . 21.1 0.0 0.2 71.7 73.9 88.3 . 89.1 32.2 . 33.1 0.0 0.4 82.6 . 80.4 94.2 . 94.8 48.2 . 46.3

[0334]

[0335] Table 1G: Lag Time from Thrombin Generation Assay with extrinsic pathway activation with 5 pM and 0.3 pM tissue factor (ASN = asundexian; Riva = rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of Lag Time (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (lABexp); Synergy (%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 1195%CI = lower limit of the 95% confidence interval for synergy)5 pM tissue factor; Lag Time 0.3 pM tissue factor; Lag Time Calc, Calc,

[0336] inh. inh

[0337] Obs. from Exp. Syn- 11 Obs. from Exp. Syn- 11 [ASN] [Riva] prolong. obs. inh. ergy 95% prolong, obs. nh. ergy 95% (pM) (pM) (xfold) (%) (%) (%) CI (xfold) (%) (%) (%) CI 1.5 0.025 1.40 1.5 1.1 0.4 0.0 1.76 9.9 6.9 3.0 0.8 1.5 0.05 1.64 2.4 1.9 0.6 0.2 1.99 12.8 8.1 4.7 3.3 1.5 0.1 1.90 3.5 3.0 0.5 -0.1 2.39 18.1 10.4 7.7 5.1 1.5 0.2 2.27 4.9 4.5 0.4 -0.3 3.01 26.1 14.6 11.5 7.5 2.5 0.025 1.38 1.5 1.1 0.3 0.0 1.89 11.5 7.8 3.7 1.6 2.5 0.05 1.65 2.5 1.9 0.6 0.2 2.07 14.0 9.0 4.9 2.2 2.5 0.1 1.97 3.7 3.0 0.7 0.2 2.52 19.8 11.3 8.4 5.4 2.5 0.2 2.28 4.9 4.4 0.5 -0.2 3.27 29.6 15.5 14.1 8.8 5.0 0.025 1.40 1.5 1.1 0.4 0.0 1.97 12.6 8.8 3.8 0.9 5.0 0.05 1.63 2.4 1.9 0.6 0.0 2.24 16.1 10.0 6.1 3.2 5.0 0.1 1.92 3.5 3.0 0.5 -0.1 2.66 21.6 12.2 9.3 5.5 5.0 0.2 2.35 5.2 4.4 0.8 -0.2 3.58 33.5 16.4 17.2 11.8

[0338]

[0339] 0.0 0.4 2.55 2.3

[0340] Table 1H: Lag Time from Thrombin Generation Assay with extrinsic pathway activation with 5 pM and 0.3 pM tissue factor (ASN = asundexian; Riva = rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of Lag Time (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Calc. inh. by ASN (IA) (%) = calculated inhibition by asundexian alone in %; Calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alone in %)

[0341] 5 pM tissue factor, Lag Time 0.3 pM tissue factor, Lag Time

[0342] Obs. Calc. inh. Calc. inh. Calc. inh. Obs. Calc. inh. Calc. inh. Calc. inh.

[0343] [ASN] [Riva] prolong, from obs. by ASN by Riva prolong, from obs. by ASN by Riva (pM) (pM) (xfold) (%) (IA) (%) (IB) (%) (xfold) (%) (IA) (%) (IB) (%) 1.5 0.0 1 05 0.2 0.2 1 44 5.7 5.6

[0344] 2.5 0.0 1 08 0.3 0.2 1 47 6.1 6.6

[0345] 5.0 0.0 1 01 0.1 0.2 1-55 7.2 7.6

[0346] 0.0 0.025 1 28 1.1 . 0.9 1 19 2.4 - 1.3 0.0 0.05 1.52 2.0 - 1.7 1.32 4.1 . 2.6 0.0 0.1 1.77 3.0 - 2.8 1.47 6.1 - 5.1 0.0 0.2 2-05 40 - 4.2 1.73 9.5 . 9.5

[0347]

[0348] 0.0 0.4 2.55 6.0 - 5.7 2.3 17.5 - 16.9

[0349] a.4) Determination of the anticoagulant effect of combinations of asundexian and rivaroxaban in the activated partial thromboplastin time (aPTT) in human plasma

[0350] The anticoagulant activity of combinations of asundexian and rivaroxaban was determined in vitro inclotting time assays in human plasma. The pooled human plasma was prepared as described under a.3). The citrated platelet-poor plasma samples of 10 healthy donors were pooled and stored at -20°C.

[0351] The time until the samples had clotted after addition of a coagulation reagent was measured mechanically in the MClOplus (Merlin Medical), a semi-automatic 10-channel ball coagulometer.

[0352] The activated partial thromboplastin time (aPTT) was determined in the pooled human plasma in the presence of varying concentrations of asundexian and / or rivaroxaban using a commercial test kit (C.K. Prest, Stago).

[0353] Solutions of asundexian or rivaroxaban in DMSO were prepared as described before so that final concentrations of 0, 0.31, 0.63, 1.25, 2.5, 5 and 10 pM of asundexian and 0, 0.013, 0.025, 0.05, 0.1 0.2, 0.4 pM of rivaroxaban in the human plasma samples were reached after addition of 1 pL of the respective compound solutions to 50 pL plasma. Thus, all in all, a matrix with 49 different combinations was generated.

[0354] Following the addition of 50 pL aPTT reagent (C.K. Prest, Stago) the mixtures were incubated at 37°C for 3 minutes. Coagulation was then started by addition of 50 pL 25 mM calcium chloride, and the time until the samples were clotted was determined. aPTT prolongations were calculated as ratio to baseline defined as the clotting time with 2 pL of the solvent DMSO alone. All measurements were conducted 4 (1.25 pM ASN) or 5 times on different days. The arithmetric means of the clotting times and the geometric means of prolongations of the different combinations versus DMSO alone as control were determined. Potential synergism was assessed as described above utilizing the Bliss Independence Model following the same approach as for Lag Time in the Thrombin Generation Assay (described in a.3)) with a maximum achievable effect (Max) of 240 s. This corresponds again to the end of the observation period in the experiment and is a reasonable choice with physiological and clinical relevance.

[0355] The data in Tables 2A and 2B and Figure 1 show that in the range of the preferred concentrations synergistic effects were observed.

[0356] Table 2A: Activated partial thromboplastin time (aPTT) (ASN = asundexian; Riva = rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of aPTT (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (LxBexp); Synergy (%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 11 95%CI = lower limit of the 95% confidence interval for synergy)aPTT

[0357] Obs. Calc. inh.

[0358] [ASN] [Riva] prolong. from obs. Exp. inh. Synergy

[0359] (HM) (HM) (xfold) (%) (%) (%) 1195% CI

[0360] 1.25 0.025 1.75 12.3 10.8 1.5 -0.1 1.25 0.05 1.83 13.7 11.3 2.4 0.6 1.25 0.1 1.92 15.3 12.2 3.1 0.4 1.25 0.2 2.12 18.5 13.2 5.3 2.7 2.5 0.025 2.15 18.8 17.2 1.6 0.7 2.5 0.05 2.24 20.3 17.7 2.6 1.4 2.5 0.1 2.37 22.4 18.5 3.9 1.9 2.5 0.2 2.61 26.4 19.5 6.9 5.0 5.0 0.025 2.60 26.2 25.0 1.1 0.1 5.0 0.05 2.74 28.3 25.5 2.8 0.9 5.0 0.1 2.90 31.1 26.2 4.9 1.9 5.0 0.2 3.21 36.2 27.1 9.1 6.2

[0361]

[0362] 0.0 0.4 1.3

[0363] Table 2B: Activated partial thromboplastin time (aPTT) (ASN = asundexian; Riva = rivaroxaban; Obs. prolong, (xfold) = Observed prolongation of aPTT (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Calc. inh. by ASN (IA) (%) = calculated inhibition by asundexian alone in %; Calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alone in %)

[0364] aPTT

[0365] Obs. Calc, inhib. Calc. inh. by Calc. inh.

[0366] [ASN] [Riva] prolong. from obs. ASN (IA) by Riva (IB) (HM) (HM) (xfold) (%) (%) (%) 1.25 0.0 1.69 11.4 10.1

[0367] 2.5 0.0 2.04 17.0 16.6

[0368] 5.0 0.0 2.48 24.2 24.5

[0369] 0.0 0.025 1.05 0.8 . 0.8 0.0 0.05 1.09 1.5 1.4 0.0 0.1 1.14 2.4 . 2.3 0.0 0.2 1.22 3.6 . 3.5 0.0 0.4 1.3 4.9 . 4.7

[0370]

[0371] a.5) Impact of combinations of asundexian and rivaroxaban on clotting times in the Whole Blood Clotting Assay

[0372] Human whole blood was drawn from healthy volunteers into containers with sodium citrate solution as described before (S-Monovette, Sarstedt), resulting in a 0.11 mM sodium citrate solution.

[0373] Solutions of asundexian or rivaroxaban in DMSO were prepared as described before so that finalconcentrations of 0, 1, 3 and 10 pM of asundexian and 0, 0.1, 0.3, 1, 3 pM of rivaroxaban in the human plasma samples were reached by addition of 1 pL of the respective compound solutions to 1 mb of whole blood.

[0374] 1 pL of DMSO solutions of each compound (either asundexian or rivaroxaban) were pipetted into a 1.5 ml tube (Eppendorff). After addition of 1 m of the fresh citrated human whole blood and cautious and thorough mixing, 10 pL of calcium chloride were added to start the clotting process. The status of the clotting process in the samples were assessed at pre-defined timepoints and recorded by a score, which included a 0 for a clot with retraction, a 1 for a completely clotted sample, a 2 for several small clots within the sample, a 3 for one initial clot within the sample, a 4 for no signs of clotting. The determination of the time, until the whole sample was clotted, was recorded, and the score over 90 min was calculated. In addition, the ratio of the time to complete clotting versus the time of a sample with DMSO only and the ratio of the score versus the score of the sample with DMSO only were calculated.

[0375] The experiments were conducted with whole blood from different healthy volunteers on 9 different days. The arithmetric means of the clotting times and the geometric means of prolongations of the different combinations versus DMSO alone as control were determined. Potential synergism was assessed as described above utilizing the Bliss Independence Model following the same approach as for Lag Time in the Thrombin Generation Assay (described in a.3)) with a maximum achievable effect (Max) of 180 min. This corresponds again to the end of the observation period in the experiment and is a reasonable choice with physiological and clinical relevance .

[0376] While rivaroxaban appears to be more potent than asundexian in this setting of static whole blood coagulation, both asundexian alone and rivaroxaban alone prolonged the clotting time in this experiment. As indicated in Tables 4A and 4B and Figure 4, several combinations of asundexian and rivaroxaban demonstrated synergistic effects.

[0377] Table 4A: Whole blood clotting time (WBCT) - time to clot: [ASN] = concentration of asundexian; [Riva] = concentration of rivaroxaban; Obs. CT(min) = observed clotting time; Obs. prolong, (xfold) = Observed prolongation (ratio to control); Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Exp. inh. (%) = expected inhibition according to Bliss Independence Model (lABexp); Synergy (%) = synergistic effect in percentage points derived from mean of the difference of observed and expected inhibition; 11 95%CI = lower limit of the 95% confidence interval for synergy)

[0378] Obs. Calc. inh.

[0379] [ASN] [Riva] Obs. CT prolong. from obs. Exp. inh. Synergy

[0380] (ftM) (pM) (min) (xfold) (%) (%) (%) 11 95% CI 1 0.1 37.2 1.93 n.4 7.9 3.6 -2.30 1 0.3 56.7 3.00 23.5 14.9 8.5 2.01 3 0.1 45.6 2.44 16.6 10.7 5.9 2.01 3 0.3 66.7 3 43 29.9 17.5 12.4 1.31

[0381]

[0382] 0.0 0.0 18.9 1Table 4B: Whole blood clotting time (WBCT) - time to clot: [ASN] = concentration of asundexian; [Riva] = concentration of rivaroxaban; Obs. CT(min) = observed clotting time; Obs. prolong, (xfold) = Observed prolongation (ratio to control) ; Calc. inh. from obs. (%) = inhibition calculated based on observed prolongation; Calc. inh. by ASN (IA) (%) = calculated inhibition by asundexian alone in %; Calc. inh. by Riva (IB) (%) = calculated inhibition by rivaroxaban alone in %)

[0383] Obs. Calc. inh. Calc. inh. by Calc. inh. [ASN] [Riva] Obs. CT prolong. from obs. ASN (IA) by Riva (IB) (pM) (pM) (min) (xfold) (%) (%) (%)

[0384] 1 0.0 25.6 1.37 4 i 4 \

[0385] 3 0.0 30.0 1.61 6.9 7

[0386] 10 0.0 33.9 1.79 94 93

[0387] 0 0.1 28.9 1.566 2. 4

[0388] 0 0.3 37.2 2.01 11.3 . 11.3

[0389] 0 1 71-7 3.75 3 0 - 32.1

[0390] 0 0 18.9 1

[0391]

[0392] A-2) Evaluation of combinations of asundexian and rivaroxaban in vivo

[0393] a.6) Determination of the antithrombotic effect of a combination of asundexian and rivaroxaban in a FeCh-induced injury model at the Arteria carotis in rabbit with simultaneous measurement of the ear bleeding time

[0394] The antithrombotic activities of the inhibitors and their combinations were tested in an arterial thrombosis model. The thrombus formation was triggered by chemically damaging a section of the carotid artery in rabbits. Simultaneously, the ear bleeding time was determined. Male rabbits (Crl (NZW)BR, Charles River) on a normal diet weighing 2.2 - 3.5 kg were anesthetized by intramuscular injection of xylazine and ketamine (Rompun, Bayer, 5 mg / kg and Ketavet, Pharmacia & Upjohn GmbH, 40 mg / kg body weight). Anesthesia was further supported by intravenous administration of the same preparations (bolus & continuous infusion) via the right ear vein.

[0395] Asundexian and rivaroxaban were dissolved in PEG 400 / ethanol / water (50 parts / 10 parts / 40 parts). The test substances were administered intravenously via the femoral vein to the anesthetized rabbits. Asundexian was given 30 minutes before the injury at a dose of 6 mg / kg. This dose was chosen because the achieved plasma concentrations are close to the one observed with the 50 mg tablet in humans after correction of differences in the unbound fraction and the potency, which leads to an aPTT prolongation of about 1.9. Rivaroxaban was given as bolus 10 min before, followed by continuous infusion. The doses of ‘rivaroxaban low’ and ‘rivaroxaban high’ were chosen to yield plasma concentrations with PT prolongations of around 1.2 and 1.7, to reflect a very low dose and a dose, which is slightly higher than the highest dose in humans, but close to the efficacy of the asundexian dose in this model. After preparation ofthe right carotid artery, vascular damage was induced by wrapping a piece of fdter paper (10 mm x 10 mm) on a strip of Parafdm® (25 mm x 12 mm) around the carotid artery without impairing blood flow. The filter paper contains 100 pL of a 13% solution of FeCh (Sigma) in water. After 5 minutes, the filter paper was removed, and the vessel was flushed twice with aqueous 0.9% sodium chloride solution. 30 minutes after the injury, the carotid artery was excised in the area of damage, and any thrombotic material present was removed and weighed. The ear bleeding time was determined 2 minutes after the injury to the carotid artery. For this, the left ear was shaved, and a defined cut of 3 mm length (Blade Art. No. 10-150-10, Martin, Tuttlingen, Germany) was made parallel to the longitudinal axis of the ear. Care was taken not to injure any visible vessels. Any blood that emerged was collected in 30-second intervals using precisely weighed pieces of filter paper, without directly touching the wound. The bleeding time was calculated as the time from the incision until no blood was detectable on the filter paper.

[0396] The results for thrombus weights and bleeding times are displayed in Figure 2 and 3 as mean ± standard deviation [SD] . Differences in thrombus weights and in bleeding times between asundexian, rivaroxaban and the combination versus control were analyzed by Kruskall-Wallis analysis followed by Dunn’s multiple comparison tests. The comparisons of the combination of asundexian and rivaroxaban versus both compounds alone were conducted by separated T-Test analyses.

[0397] As shown in Table 3 and in Figure 2 and Figure 3, asundexian and ‘rivaroxaban high’ share similar thrombus weight reductions of around 70-75%, but while asundexian did not show any impact on the bleeding time, rivaroxaban prolonged it 2-fold. Administration of ‘rivaroxaban low’ did not result in a thrombus weight reduction. However, synergistic effect were achieved, when asundexian and ‘rivaroxaban low’ were administered together, resulting in an almost complete reduction of the thrombi, significant differences in thrombus weight versus individual treatments with either one compound and a synergistic effect calculated from the difference between observed and expected effect.Table 3 : Synergistic antithrombotic effect of the combination of asundexian with rivaroxaban combination of

[0398] rivaroxaban rivaroxaban control asundexian asundexian and

[0399] low high (n=13) (n=13) rivaroxaban low

[0400] (n=6) (n=6) (n=6)

[0401] asundexian

[0402] - 6 mg / kg 6 mg / kg

[0403] (bolus)

[0404] rivaroxaban

[0405] 0.03mg / kg + 0.03mg / kg + 0.24mg / kg + (bolus,

[0406] 0.036 mg / kg / h 0.036 mg / kg / h 0.27 mg / kg / h infusion)

[0407] Thrombus

[0408] weight 0% 70% 95% 1.4 % 75% reduction

[0409] statisticalvs-Contro1P< 0.001 P< 0.001 n.s. P< 0.001 significance

[0410] vs. Combi P< 0.05 P< 0.001 synergy 25%

[0411] bleeding time prolongation 1 1.16 1.18 1.22 2.17 statistical significance n.s. n.s. n.s. P< 0.05

[0412]

[0413] n.s.: not significant

[0414] a.7) Determination of the antithrombotic effect of a combination of asundexian and rivaroxaban in a ‘large arterio-venous shunt’ model in rabbit with simultaneous measurement of the ear bleeding time The antithrombotic activities of asundexian and rivaroxaban and their combination were tested in a rabbit model of arterio-venous shunt thrombosis caused by low flow and / or flow disturbances in a large-diameter shunt connecting the femoral artery with the femoral vein. Simultaneously, the ear bleeding times were measured.

[0415] As in a.6), male rabbits (Crl (NZW)BR, Charles River) on a normal diet were anesthetized by intramuscular injection of xylazine and ketamine (Rompun, Bayer, 5 mg / kg and Ketavet, Pharmacia & Upjohn GmbH, 40 mg / kg body weight). Anesthesia was further supported by intravenous administration of the same preparations (bolus & continuous infusion) via the right ear vein. The left femoral artery and vein were surgically exposed and prepared for implantation of a 15-cm piece of a Vygon 07Fr-L.38cm REF 270.07 catheter, which was connected to a 30 cm piece of PE 160. The center piece of the catheter consisted of an 8 cm Tygon T3610-23 (ED. 5 / 16", O.D. 7 / 16", Wall 1 / 16") piece containing a 16 cm loop of Nylon wire (Mitchell fishing line, 0.14 mm diameter, roughened by sand paper P320). After tight implantation in the vein and in the artery the whole tubing was filled with physiologic saline. The large diameter tubing was placed 25 cm above the animal, thereby further reducing the blood flow in the shunt. Asundexian and rivaroxaban were administered intravenously to as described in a.6). Thrombus formation was started by opening the shunt. 60 minutes after shunt opening, potential thrombi in the shunt were harvested andweighed. A defined ear incision was conducted to start the bleeding time measurements (see a.6)). The bleeding time was calculated as the time from the incision until no more blood was detectable on the filter paper, which was changed in 30 second intervals for up to 15 min.

[0416] Mean values of the thrombi with standard deviation were calculated (n=6-7). The results for thrombus weights and bleeding times are displayed in Figure 5 and Figure 6 as mean ± standard deviation [SD], Differences in thrombus weights and in bleeding times between control and verum groups were analyzed by Kruskal Wallis analysis followed by Dunn’s multiple comparison tests. The comparisons of the combination of asundexian and rivaroxaban versus both compounds alone were conducted by separated T- Test analyses.

[0417] As shown in Table 5 and in Figure 5 and Figure 6, asundexian (ASN) and ‘rivaroxaban low’ (‘Riva low’) share similar thrombus weight reductions of around 33 - 35%. However, synergistic effects were achieved, when asundexian and ‘rivaroxaban low’ were administered together, resulting in 77% reduction of thrombus weight, a significantly improved effect versus control and single component administration. A synergistic effect calculated from the difference between observed and expected effect (following the determination of the expected effect via the Bliss Independence model) was identified (Table 5).

[0418] As shown in Table 5, in this low flow / flow disturbance model in rabbit, none of the single compound administrations yielded significant thrombus weight reductions, while the combination of asundexian and low-dose rivaroxaban achieved significant thrombus weight reductions without increasing the ear bleeding times versus control.

[0419] Table 5: Synergistic antithrombotic effect of the combination of asundexian with rivaroxaban in ‘large AV- shunt’ model in rabbit

[0420] combi ASN &

[0421] control ASN ‘riva low’ ‘riva low’

[0422] Number of animals (n) 7 6 6 6 ASN (bolus; mg / kg) 0 6 6 0 Riva (bolus + continuous infusion; 0 0 0.03 + 0.036 0.03 + 0.036 mg / kg + mg / kg / h)

[0423] Thrombus reduction (%)* 0 33.0 77.0 34.9 P vs. Control** n.s. P< 0.01 n.s.

[0424] P vs. Combi*** P< 0.01 P< 0.01 Synergy (% points) 20.6

[0425] Bleeding time prolong, (xfold)* 1 1.03 1.16 1.19 P vs. Control** n.s. n.s. n.s.

[0426]

[0427] *mean, ** Kruskal -Wallis test with Dunn’s mu tiple comparison test, ***Mann -Whitney test, n.s. non- significanta.8) Determination of the antithrombotic effect of a combination of asundexian and rivaroxaban in a ‘hypercoagulable state’ model in baboon

[0428] Several investigations suggest that a potential increase in coagulability due to thrombo -inflammatory processes in the blood could have a role in atrial thrombogenesis. To evaluate the impact of the combinations of asundexian and rivaroxaban on thrombus formation triggered via hypercoagulable states in blood, a baboon model was conducted with FXa / PCPS as a trigger for hypercoagulation. Due to its strong and short-time character, this injection of FXa / PCPS allows for the mechanistic evaluation of asundexian, rivaroxaban and the combination of both in the presence of a strong hypercoagulable challenge, which leads to a near-complete consumption of fibrinogen and platelets in control animals within 10 minutes. In this study, activated FXa at a dose of 45 pM / kg and a mix of phosphatidylserine and -cysteine (PCPS) at a dose of 79.2 nM / kg, both given as i.v. bolus, were used to initiate hypercoagulation. Consequently, a strong activation of the coagulation system was observed in previous studies, resulting in a near-complete consumption of fibrinogen and platelets in control animals within 5 - 10 minutes, as planned.

[0429] The onset of treatment with either asundexian, rivaroxaban or both was 30 min before the initiation of the hypercoagulation. The animals were kept in anesthesia for 8 h, the experiment stopped after 24 h. Blood was taken at -30, 0, 5, 10, 15, 30, 60, 90, 120, 240, 360, 480, and 1440 min (time scale adjusted to the initiation hypercoagulation as 0 min).

[0430] Five groups of three animals were tested: In addition to the control group, an asundexian group was treated with a dose of 2 mg / kg as i.v. bolus to achieve 2.0 - 2.2-fold prolongation of the aPTT in the first hour in healthy animals. A ‘high dose’ of rivaroxaban was administered as 0.22 mg / kg i.v. bolus with continuous infusion of 0.22 mg / kg / h for the following two hours to achieve PT prolongations close to the 20 mg tablet in humans. A ‘low dose’ of rivaroxaban was administered as 0.045 mg / kg i.v. bolus with continuous infusion of 0.045 mg / kg / h for the following two hours to achieve PT prolongations around 1.1 -1.2 in healthy animals. This low PT prolongation is in the range of the low doses of rivaroxaban, such as the 2.5 mg twice daily dose.

[0431] After completion of the in-life part, first analyses of the platelet count data are depicted in Figure 7: As expected, in the control group a loss of platelets occurred with a trough below 20% remaining platelets at 5 min. The platelet count was almost back to normal at the end of the experiment. In contrast, the animals with rivaroxaban at the high dose experienced no platelet loss. Animals in the Tow rivaroxaban’ group experienced a significant platelet count loss to below 50%. In the ‘asundexian alone’ group, no effect on the platelet count drop was observed. While ‘asundexian alone’ showed no effect and ‘low dose’ rivaroxaban only prevented half of the platelet loss, their combination resulted in a short 30% drop, which returned to almost-normal very soon after.

[0432] Thus, this combination of 2 mg / kg asundexian and 0.045 mg / kg + 0.045 mg / kg / h rivaroxaban, simulating a dose of asundexian between once and twice daily 50 mg and a low dose of rivaroxaban, demonstratedstrong synergistic effects in this model of systemic hypercoagulation in baboons.

[0433] In the baboon hypercoagulation model, asundexian alone showed no effect on platelet loss and low-dose rivaroxaban showed partial effect, while the combination of both drugs demonstrated superior efficacy.

[0434] Comparision Experiments: Combination of asundexian with apixaban

[0435] The experiment with a combination of asundexian and apixaban was performed according to a.6) Determination of the antithrombotic effect of a combination of asundexian and rivaroxaban in a FcCF-induced injury model at the Arteria carotis in rabbit with simultaneous measurement of the ear bleeding time, mentioned above. The results are shown in Table 6 and Figure 8 und Figure 9.

[0436] Table 6: Effects of the combination of asundexian with apixaban in the FeCh- induced injury model (ASN = asundexian, Apixa = apixaban)

[0437] combi of combi of Apixa ASN & ASN & control ASN Apixa

[0438] ‘high’ Apixa Apixa (n=16) (n=16) ,low‘

[0439] (n=6) ‘high’ ‘low’

[0440] (n=6) (n=6) asundexian

[0441] - 6 mg / kg 6 mg / kg 6 mg / kg (bolus)

[0442] apixaban

[0443] 0.3mg / kg 0.3mg / kg 0.1 mg / kg 0.1 mg / kg (bolus)

[0444] Thrombus

[0445] 0% 70% 23% 91% 27% 57% weight

[0446] reduction*

[0447] . .. .. . vs. Control** P< 0.0001 n.s. P< 0.0001 n.s. P< 0.01 statistical

[0448] significance P< 0.01

[0449] vs. Combi***#

[0450] P< 0.01 P<0.05

[0451] n.s.##

[0452] Synergy 14 %

[0453] Bleeding time prolongation* 1 1.15 1.18 1.70 1.11 1.11

[0454] P<0.01 statistical significance n.s. n.s. n.s. n.s.

[0455]

[0456] * mean, ** Kruskal-Wallis test with Dunn’s multiple comparison test, ***Mann -Whitney test, n.s. nonsignificant,#in combi with Apixa ‘low’,##in combi with Apixa ‘high’

[0457] The experiment with a combination of asundexian and apixaban was performed according to a.7) Determination of the antithrombotic effect of a combination of asundexian and rivaroxaban in a ‘large arterio-venous shunt’ model in rabbit with simultaneous measurement of the ear bleeding time, mentioned above. The results are shown in Table 7 and Figure 10 anf Figure 11.Table 7: Effects of the combination of asundexian with apixaban in the Targe arterio-venous shunt’ model in rabbit (ASN = asundexian, Apixa = apixaban)

[0458] combi of combi of

[0459] Apixa ASN & control ASN Apixa ‘low’ ASN &

[0460] ,high‘ Apixa (n=7) (n=6) (n=8) Apixa ‘low’

[0461] (n=5) ‘high’ (n=7)

[0462] (n=3) asundexian (bolus) - 6 mg / kg 6 mg / kg 6 mg / kg apixaban (bolus + 0.1 mg / kg + 0.1 mg / kg + 0.3 mg / kg + 0.3 mg / kg + cont.infusion) 0.1 mg / kg / h 0.1 mg / kg / h 0.3 mg / kg / h 0.3 mg / kg / h Thrombus

[0463] weight 0% 33% 25% 62% 55% 87% reduction*

[0464] . .. .. . vs. Control** n.s. n.s. P< 0.05 n.s. P< 0.01 statistical

[0465] significance P< 0.05

[0466] vs. Combi***#

[0467] P< 0.05 P<0.05

[0468] P< 0.05##

[0469] synergy 3.5 % 18 % bleeding time

[0470] 1 1.03 1.37 1.53 1.93 1.89 prolongation*

[0471] statistical significance n.s. n.s. P<0.05 P<0.01 P<0.01

[0472]

[0473] * mean, ** Kruskal-Wallis test with Dunn’s multiple comparison test, ***Mann -Whitney test, n.s. nonsignificant,#in combi with Apixa ‘low’,##in combi with Apixa ‘high’

[0474] B) Preparation examples

[0475] Asundexian

[0476] The preparation of asundexian is described in W02017 / 005725 in example 235.

[0477] WO2022 / 189279 describes the crystalline forms of asundexian. WO2014 / 154794 and W02017 / 005725 describe a synthesis for preparing asundexian.

[0478] Rivaroxaban

[0479] The preparation of rivaroxaban is described in WOOl / 47919 in example 44.

[0480] Comparison Example Apixaban

[0481] Apixaban is l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-l-yl)phenyl]- 4,5,6,7-tetrahydro-lH-pyrazolo[3,4-c]pyridine-3-carboxamide. The preparation of apixaban, brand name Eliquis®, is described in WO03 / 026652 in example 18.

[0482]

[0483] Apixaban is a Factor Xa inhibitor. Factor Xa inhibitors (FXa inhibitors) can preferably be employed in medicaments for the treatment and / or prevention of thrombotic or thromboembolic disorders. Apixaban is approved as 10 mg twice daily therapy for treatment of existing deep vein thrombosis (DVT) or pulmonary embolisms (PE) for the first 7 days (followed by 5 mg twice daily), as 5 mg twice daily for the reduction in the risk of stroke / systemic embolism in patients with non-valvular atrial fibrillation, as 2.5 mg twice daily for the reduction in the risk of recurrent DVT / PE following initial therapy, for the prophylaxis of DVT, which may lead to PE, following hip or knee replacement surgery, and if dose adjustment for atrial fibrillation patients is needed.

[0484] The effect of apixaban was shown in in vivo models of venous and arterial thrombosis (Wong P et al., Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. JTH 2008; 6 820-29).

[0485] Explanation of the figures:

[0486] Figure 1: Anticoagulant effect of combinations of asundexian and rivaroxaban in aPTT in human plasma (aPTT as clotting time in s, depicted as arithmetic mean ± standard deviation [SD] n=5-6)

[0487] Figure 2: Thrombus weight reduction in a FcCF-induccd injury model at the Arteria carotis in rabbit (Riva = rivaroxaban)

[0488] Figure 3: Bleeding time in an ear bleeding time model in rabbit (Riva = rivaroxaban)

[0489] Figure 4: Evaluation of combinations of asundexian and rivaroxaban in Whole blood clotting time assay (n=9; control: n=18; mean; 95% confidence interval)

[0490] Figure 5: Impact of asundexian and rivaroxaban and their combination on the thrombus weight in a large AV-shunt model between femoral artery and -vein (Riva = rivaroxaban, ASN=asundexian, n=6-7, mean, SD)

[0491] Figure 6: Impact of asundexian and rivaroxaban and their combination on bleeding time in an ear bleeding time model in rabbit (Riva = rivaroxaban, ASN=asundexian, n=6-7, mean, SD)

[0492] Figure 7: Evaluation of the impact of the combinations of asundexian and rivaroxaban on the platelet loss in whole blood after initiating hypercoagulable state by FXa / PCPS (Riva = rivaroxaban, ASN =asundexian,n=3, mean, SD);

[0493]

[0494] XaPCPS (control) (n=3), + Riva 0.22 mg / kg, 0.22 mg / kg / h (n=2), + Riva 0.045 mg / kg, 0.045 mg / kg / h (n=3), + ASN 2 mg / kg (n=3), * + ASN 2 mg / kg + Riva 0.045 mg / kg, 0.045 mg / kg / h (n=3)

[0495] Figure 8: Thrombus weight reduction in a FcCb-induccd injury model at the Arteria carotis in rabbit (ASN = asundexian, Apixa = apixaban)

[0496] Figure 9: Bleeding time in an ear bleeding time model in rabbit (ASN = asundexian, Apixa = apixaban) Figure 10: Impact of asundexian and apixaban and their combination on the thrombus weight in a large AV-shunt model between femoral artery and -vein (ASN = asundexian, Apixa = apixaban, n=6-7, mean, SD)

[0497] Figure 11: Impact of asundexian and rivaroxaban and their combination on bleeding time in an ear bleeding time model in rabbit (ASN = asundexian, Apixa = apixaban, n=6-7, mean, SD)

Claims

Claims1. A combination comprising asundexian, the compound of the formula (I)or a hydrate, solvate, or a pharmaceutically acceptable salt thereof, andrivaroxaban, the compound of the formula (II)or a hydrate, solvate, or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, characterized in that the combination comprises asundexian and rivaroxaban.

3. The combination as claimed in claim 1 or 2, characterized in that the combination is a fixed combination.

4. The combination as claimed in claim 1 or 2, characterized in that the combination is a non-fixed combination.

5. A process for producing a combination as claimed in any of claims 1 to 4, characterized in that asundexian and rivaroxaban are combined or prepared in a suitable way.

6. A combination as claimed in any of claims 1 to 4 for the treatment and / or prevention of thrombotic or thromboembolic disorders.

7. A medicament comprising a combination as claimed in any of claims 1 to 4 and one or more pharmacologically suitable excipients and / or carriers.

8. A combination as claimed in any of claims 1 to 4 for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders.

9. A combination as claimed in any of claims 1 to 4 for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke and ischemic strokes includingcardioembolic strokes,such as strokes in patients with atrial fibrillation,non-cardioembolic strokes,such as strokes due to large or small artery diseases,or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA.

10. A combination as claimed in any of claims 1 to 4 for the use in the treatment and / or prevention of stroke or systemic embolism in patients with atrial fibrillation.

11. A combination as claimed in any of claims 1 to 4, characterized in that the combination comprises asundexian in an amount of 50 to 100 mg and rivaroxaban in an amount of 2.0 to 5.0 mg.

12. A combination as claimed in any of claims 1 to 4, characterized in that the combination comprises asundexian in an amount of 100 mg, where the 100 mg are given two times a day at 50 mg each, and rivaroxaban in an amount of 2.0 mg, where the 2.0 mg are given two times a day at 1.0 mg each.

13. A combination as claimed in claim 11 or 12 for the use in the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke, ischemic strokes includingcardioembolic strokes,such as strokes in patients with atrial fibrillation,non-cardioembolic strokes,such as strokes due to large or small artery diseases,or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA.

14. The combination as claimed in any of claims 1 to 4, 11 or 12 for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders.

15. The combination as claimed in any of claims 1 to 4, 11 or 12 for use in a method for the treatment and / or prevention of thrombotic or thromboembolic disorders related to occlusions in the cerebrovascular arteries, such as transitory ischemic attacks (TIA), thrombotic stroke and thromboembolic stroke, ischemic strokes includingcardioembolic strokes,such as strokes in patients with atrial fibrillation,non-cardioembolic strokes,such as strokes due to large or small artery diseases,or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA.